Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADS: Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
NCT05436535Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab, triamcinolone acetonide, Alkindi Sprinkle in atopic dermatitis (AD), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05436535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436535.